

First Participant Recruited in DiagnosTear (subsidiary) Clinical Trial in India

19th October, 2021

DiagnosTear Ltd, a subsidiary of BioLight is proud to announce that on the 18th of October, 2021, has recruited its first participant in India for its clinical trial of diagnosing Dry Eye Syndrome (DES).

The trial is part of an agreement signed between DiagnosTear, LV Prasad Eye Institute (**LVPEI**), a leading ophthalmic medical center in India and a global pharmaceutical company in June 2020 for the examination of a potential collaboration. (The Agreement) (The Trial)

DiagnosTear is engaged in the development of TeaRx[®] Technology designed to diagnose various diseases of the front of the eye by a multi parameter objective examination of the composition of the tear fluid. Its first indication is personalization and follow-up treatment for dry eye syndrome (DES) (“DiagnosTear Product”).

The main objectives of the clinical trial are to examine DiagnosTear’s capabilities in the diagnosis of patients suffering from DES, while identifying the various characterizations and background of DES for a more accurate, focused and efficient treatment. The trial is expected to include 500 patients and 100 healthy volunteers with a follow up of up to 6 months.

Forward-Looking Information Statement - The information, expectations and assessments of DiagnosTear and the Company above including the conduct of the experiment in India due the existing restrictions as a result of the Corona epidemic, the rate of recruitment of participants, the date of completion of the experiment, and the examination of the possibility of continued cooperation, and including the significance of achieving which of the main objectives of the experiment (if any) including forecasts, deadlines, estimates and/or DiagnosTear and/or the Company's plans in connection therewith are forward-looking information within the meaning of the Securities Law, 5728-1968, based on among others, high uncertainty, on third parties and many variables that DiagnosTear and/or the Company do not have necessarily control over, and therefore it is possible that the information and assessments as aforesaid, in practice will not be realized and/or will not be fully realized and/or will be realized in a manner materially different from what was assessed or observed in the first place, including the realization of any of the risk factors as specified in section 5.14 of the Company's Annual 2020 Report, which may have a significant effect, jointly and separately on DiagnosTear assessments and intentions of the said Company.

About DiagnosTear

DiagnosTear’s TeaRx[™] technology is a diagnostic platform intended for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops. The first indication is for identification, personal matching and monitoring of Dry Eye Syndrome (DES).

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye diseases and their treatment. BioLight’s portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies. The Ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.